



UNIVERSITÀ  
DEGLI STUDI  
FIRENZE

## FLORE

# Repository istituzionale dell'Università degli Studi di Firenze

### **Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary**

Questa è la versione Preprint (Submitted version) della seguente pubblicazione:

*Original Citation:*

Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome / Trpkov, Kiril\*; Hes, Ondrej; Agaimy, Abbas; Bonert, Michael; Martinek, Petr; Magi-Galluzzi, Cristina; Kristiansen, Glen; Lüders, Christine; Nesi, Gabriella; Compérat, Eva; Sibony, Mathilde; Berney, Daniel M.; Mehra, Rohit; Brimo, Fadi; Hartmann, Arndt; Husain, Arjumand; Frizzell, Norma; Hills, Kirsten; Maclean, Fiona; Srinivasan, Bhuvana;

*Availability:*

This version is available at: 2158/1116837 since: 2018-03-03T13:53:54Z

*Published version:*

DOI: 10.1097/PAS.0000000000000617

*Terms of use:*

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

*Publisher copyright claim:*

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

(Article begins on next page)

1  
2  
3  
4 **Fumarate Hydratase-deficient Renal Cell Carcinoma is Strongly Correlated with *Fumarate***  
5  
6 ***Hydratase* Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome**  
7  
8  
9

10  
11  
12 Kiril Trpkov MD FRCPC<sup>1</sup>, Ondrej Hes MD, PhD<sup>2</sup>, Abbas Agaimy MD<sup>3</sup>, Michael Bonert MD  
13 FRCPC<sup>1</sup>, Petr Martinek MSc<sup>2</sup>, Cristina Magi-Galluzzi MD, PhD<sup>4</sup>, Glen Kristiansen MD<sup>5</sup>,  
14  
15 Christine Lüders MD<sup>5</sup>, Gabriella Nesi MD<sup>6</sup>, Eva Comperat MD<sup>7</sup>, Mathilde Sibony MD<sup>8</sup>, Daniel  
16  
17 M Berney MD<sup>9</sup>, Rohit Mehra MD<sup>10</sup>, Fadi Brimo MD FRCPC<sup>11</sup>, Arndt Hartmann MD<sup>3</sup>,  
18  
19 Arjumand Husain MD FRCPC<sup>1</sup>, Norma Frizzell PhD<sup>12</sup>, Kirsten Hills FRCPA<sup>13</sup>, Fiona Maclean  
20  
21 FRCPA<sup>14</sup>, Bhuvana Srinivasan, MD, FRCPA<sup>15</sup>, Anthony J Gill MD, FRCPA<sup>16</sup>  
22  
23  
24  
25  
26  
27

28  
29 <sup>1</sup>Calgary Laboratory Services and University of Calgary, Calgary, AB, Canada; <sup>2</sup>Charles  
30  
31 University, Pilsen, Czech Republic; <sup>3</sup>Institute of Pathology, Friedrich-Alexander-University,  
32  
33 Erlangen, Germany; <sup>4</sup>Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland  
34  
35 Clinic, Cleveland, OH; <sup>5</sup>University Clinic Bonn, Germany; <sup>6</sup>Carregi Hospital, Florence, Italy;  
36  
37 <sup>7</sup>Pitié-Salpêtrière Hospital, Paris, France; <sup>8</sup>Hopital Cochin, Paris, France; <sup>9</sup>Barts Cancer Institute,  
38  
39 Queen Mary University of London, London, United Kingdom; <sup>10</sup>University of Michigan, Ann  
40  
41 Arbor, MI; <sup>11</sup>McGill University, Montreal, QC, Canada; <sup>12</sup>University of South Carolina School  
42  
43 of Medicine, Columbia, SC, <sup>13</sup>Sullivan Nicolaidis Pathology, Gold Coast, Qld, Australia,  
44  
45 <sup>14</sup>Douglass Hanly Moir Pathology, North Ryde, NSW, Australia; <sup>15</sup>Mater Hospital, South  
46  
47 Brisbane, Qld, Australia; <sup>16</sup>Cancer Diagnosis and Pathology Group, Kolling Institute of Medical  
48  
49 Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

60 **Running title:** Fumarate hydratase-deficient renal cell carcinoma  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8 **Key Words:** renal cancer; HLRCC; fumarate hydratase; FH, fumarate hydratase-deficient RCC;  
9  
10 succination; 2SC  
11  
12  
13  
14  
15

16  
17 **Correspondence:**  
18  
19

20 Kiril Trpkov, MD, FRCPC, Department of Pathology and Laboratory Medicine, Calgary  
21  
22 Laboratory Services and University of Calgary, Rockyview General Hospital, 7007 14 Street,  
23  
24 Calgary, AB, Canada, T2V 1P9; Email: [kiril.trpkov@cls.ab.ca](mailto:kiril.trpkov@cls.ab.ca); Tel: +1 403 943 3443; Fax:  
25  
26 +1 403 943 3333  
27  
28  
29  
30  
31  
32

33 **Funding disclosures and conflicts of interest:**  
34  
35

36 Study was supported in part by Calgary Laboratory Services, by Charles University Research  
37  
38 Fund (project number P36), by the project CZ.1.05/2.1.00/03.0076 from the European Regional  
39  
40 Development Fund and by the Cancer Institute NSW through the Sydney Vital Translational  
41  
42 Cancer Research Centre.  
43  
44

45  
46  
47 Authors have no other funding disclosures or conflicts of interest to report.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Abstract**  
5  
6  
7

8 Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome-associated RCC are  
9 difficult to diagnose prospectively. We used immunohistochemistry (IHC) to identify FH  
10 (Fumarate Hydratase)-deficient tumors (defined as FH negative, 2-succinocysteine (2SC)  
11 (Fumarate Hydratase)-deficient tumors (defined as FH negative, 2-succinocysteine (2SC)  
12 positive) in cases diagnosed as “unclassified RCC, high grade or with papillary pattern”, or  
13 “papillary RCC type 2”, from multiple institutions. 124 tumors (from 118 patients) were  
14 evaluated by IHC for FH and 2SC. An FH deficiency was found in 24/124 (19%) cases. An  
15 indeterminate result (only one marker abnormal) was found in 27/124 (22%) cases. In a TMA of  
16 776 RCCs of different types, only 2 (0.5%) tumors, initially considered papillary type 2, were  
17 FH-deficient. *FH* mutations were found in 19/21 FH-deficient tumors (9 confirmed germline)  
18 and in 1/26 FH indeterminate tumors identified by IHC. No *FH* mutations were found in 2/21  
19 FH-deficient RCC, 25/26 FH indeterminate RCC and 10/10 RCC demonstrating FH expression  
20 by IHC. Patients with FH-deficient RCC had median age of 44 years (range 21 to 65). Average  
21 tumor size was 8.2cm (range 0.9 to 18cm). FH-deficient RCC were characterized by at least  
22 focal macronucleoli and demonstrated two or more growth patterns in 93% cases. Papillary was  
23 the most common (74%) and dominant (59%) pattern, while other common patterns included:  
24 solid (44%), tubulocystic (41%), cribriform (41%) and cystic (33%). At presentation, 57% were  
25 stage  $\geq$ pT3, 52% had positive nodes, and 19% had distant metastases. After mean follow-up of  
26 27 months (range 1-114 months), 39% of patients were dead of disease and 26% had disease  
27 progression. We conclude that FH and 2SC are useful IHC ancillary tools which allow  
28 recognition of FH-deficient RCC.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

Hereditary leiomyomatosis and renal cancer syndrome (HLRCC) is an autosomal dominant disorder characterised by inherited predisposition to uterine and cutaneous leiomyomas and renal cell carcinoma (RCC). It is characterized by inactivating germ-line mutation in the *fumarate hydratase (FH)* gene, which is located at 1q42.3-q43 and codes for an enzyme involved in the tricarboxylic acid cycle, which hydrates fumarate to form malate. (1-6) Although the hereditary association with multiple leiomyomas of the skin has been known for more than 60 years now,(7) the first syndromic association of uterine and skin leiomyomas with renal carcinoma was reported in 2001 in two families from Finland.(2, 5) HLRCC-associated RCC was included in the 2004 WHO classification of renal neoplasms (8), however not as a distinct RCC subtype, but as a presumed hereditary counterpart of papillary RCC type. Subsequent publications highlighted the aggressive behaviour of the renal carcinomas associated with HLRCC syndrome and expanded its morphologic spectrum, emphasizing the presence of orangiphilic or eosinophilic macronucleoli with perinucleolar halos (viral inclusions-like).(9, 10) HLRCC syndrome-associated RCC is currently recognized as a separate entity in the 2013 International Society of Urological Pathology (ISUP) Vancouver Classification of renal tumors(11) and it is included in the upcoming WHO classification 2016.

Biallelic inactivation due to *FH* mutations in HLRCC syndrome results in either complete loss or reduction of the FH enzymatic activity, which leads to accumulation of the intracellular levels of fumarate.(4, 12) The increased level of fumarate modifies the cysteine residues in many proteins, resulting in increased protein succination and production of S-(2-succino)-cystein (2SC), which can be used as a marker for detection of these FH-deficient tumors.(13) Accumulation of high

1  
2  
3  
4 levels of 2SC, resulting in positive 2SC immunohistochemistry (IHC) staining, was shown to be  
5  
6 highly specific for detection of HLRCC-associated RCC.(14) The loss of FH enzymatic activity,  
7  
8 resulting in negative fumarate hydratase staining on IHC was also demonstrated to have a high  
9  
10 specificity in identifying HLRCC-associated tumors.(15, 16) However, a combined IHC  
11  
12 approach to investigate the utility of both 2SC and FH antibodies in detecting previously  
13  
14 unknown HLRCC-associated RCC has so far not been reported.  
15  
16  
17  
18  
19  
20

21 Although the primary morphologic pattern described in HLRCC-associated RCC is papillary,  
22  
23 these tumors have been shown to demonstrate many growth patterns, often in combination,  
24  
25 which can also present a diagnostic challenge when evaluating neoplasms with unknown clinical  
26  
27 or familial background.(9, 10, 14) Because of their rarity and diagnostic difficulties in  
28  
29 identifying these tumors, we postulated that many of them are currently under recognized, under  
30  
31 reported or misclassified and we sought to evaluate the utility of IHC for 2SC and FH in  
32  
33 identifying these tumors, particularly in cases signed out either as “unclassified RCC, high  
34  
35 grade”, “unclassified RCC with papillary pattern”, or “type 2 papillary RCC”. We also describe  
36  
37 the pathological features, *FH* mutational status and the clinical features of RCCs demonstrating  
38  
39 lack of FH expression (*fumarate hydratase-deficient RCC*), characterized by FH negative and  
40  
41 2SC positive staining on IHC.  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **Material and Methods**

51  
52  
53 An institutional Ethics Review was obtained for the study.  
54  
55  
56  
57

### 58 ***Pathology identification of cases***

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 We initiated an international collaboration and deliberately searched for renal neoplasms labelled  
5  
6 in the initial sign-out as “unclassified RCC, high grade” or “unclassified RCC with papillary  
7  
8 pattern” or type 2 papillary RCC. In particular, we searched for tumors exhibiting: 1) aggressive  
9  
10 features, such as invasion into perirenal or sinus fat and/or showing regional metastatic disease;  
11  
12 2) at least focal macronucleoli, and 3) presence of different growth patterns, all of which were  
13  
14 previously associated with HLRCC-associated RCC. Although many of the participating  
15  
16 collaborators had large in-house and consult practices with subspecialty interest in urologic  
17  
18 pathology, the search of the respective institutional databases was subject to varying digital  
19  
20 archive limitations for retrospective searches. All potential cases were reviewed by two urologic  
21  
22 pathologists and a representative tissue block was retrieved for additional studies. We also  
23  
24 included 2 previously confirmed and published HLRCC-associated RCC.(17, 18)  
25  
26  
27  
28  
29  
30  
31 Clinicopathologic and follow-up data were collected on cases demonstrating IHC profile  
32  
33 compatible with FH deficiency, by review of the institutional records and by contacting the  
34  
35 consulting pathologists.  
36  
37  
38  
39  
40

#### 41 ***TMA evaluation of papillary RCC enriched cohort***

42  
43 Using tissue microarray (TMA) methodology, a total of 776 renal neoplasms from three separate  
44  
45 institutions were evaluated by IHC for FH and 2SC. TMAs were enriched for papillary RCC  
46  
47 (381), comprising 175 papillary RCC type 1, 68 type 2, 39 mixed and 99 papillary RCC, not  
48  
49 specified. TMAs also included other renal tumor types: clear cell RCC (232), chromophobe RCC  
50  
51 (21), oncocytoma (25), other RCC (39), and urothelial carcinoma (78). TMAs were constructed  
52  
53 using 0.6 or 1 mm cores in duplicate or triplicate for each neoplasm (with built-in controls).  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 ***FH and 2SC Immunohistochemistry***  
5

6 IHC for FH and 2SC was performed in one laboratory on formalin fixed paraffin embedded  
7 (FFPE) sections. We used a commercially available primary anti-FH mouse monoclonal  
8 antibody (1 in 2000 dilution; clone J-13, cat no sc-100743, Santa Cruz Biotechnology, USA) and  
9 an anti-2SC rabbit polyclonal antibody (1:2000, antibody provided by Dr. Norma Frizzell) on an  
10 automated staining platform—the Leica Bond III Autostainer (Leica Biosystems, Mount  
11 Waverley, Victoria, Australia). For FH, heat induced epitope retrieval (HIER) was performed  
12 for 30 minutes at 97 degrees Celsius in the manufacturer’s alkaline retrieval solution ER2 (VBS  
13 part no: AR9640). For 2SC, HIER was performed for 30 minutes at 97 degrees Celsius in the  
14 manufacturer’s acidic retrieval solution ER1 (VBS part no.AR9961).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 FH and 2SC IHC were scored independently by two pathologists (KT and AG) on whole slide  
31 sections from tumors with “unclassified, high grade”, or “unclassified with papillary pattern”  
32 diagnosis, as per study design. Absent staining for FH in the neoplastic cells, in the presence of a  
33 positive internal control in blood vessels, inflammatory cells, other stromal cells, and non-  
34 neoplastic cells of the kidney parenchyma was interpreted as true negative staining (loss or FH-  
35 deficient status). All other patterns of staining were considered positive, provided the staining  
36 was cytoplasmic and granular (that is mitochondrial). Staining for 2SC on cases evaluated on  
37 whole section was scored as negative (0); (1+) if focal (<50% of cells reactive) or diffuse (>50%  
38 of cells reactive) but of weaker intensity; or (2+) if diffuse positive (>50% of cells reactive) with  
39 moderate to strong intensity. In positive 2SC cases, we also attempted to localize the reactivity  
40 (cytoplasmic, nuclear or both). Negative staining in the adjacent normal renal parenchyma was  
41 considered an internal negative control. Due to the limited amount of available tissue in the TMA  
42 evaluated cases, 2SC was only scored as negative or positive.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7 Positive IHC result was considered when both antibodies showed pattern indicating FH  
8  
9 deficiency (FH -, 2SC 2+); negative IHC result was when FH antibody showed retained FH  
10  
11 expression and 2SC was not expressed (FH +, 2SC 0). Indeterminate IHC result, was considered  
12  
13 when only one of the markers showed aberrant expression status suggesting FH deficiency, while  
14  
15 the other was equivocal or negative (FH +, 2SC 1+ to 2+; or FH -/+, 2SC 2+).  
16  
17  
18  
19  
20

### 21 ***Molecular evaluation of FH mutations***

22  
23 All cases with available tissue that demonstrated FH deficiency (FH -, 2SC 2+) or showed  
24  
25 indeterminate result (only one antibody reactive), underwent molecular evaluation of *FH* gene  
26  
27 mutation status by Sanger sequencing and loss of heterozygosity (LOH) studies on DNA  
28  
29 extracted from macrodissected FFPE tissue. We also evaluated 10 cases with retained FH  
30  
31 expression for *FH* mutation, as a negative control group. For Sanger sequencing previously  
32  
33 described custom primer sets were used and the whole coding sequence including exon-intron  
34  
35 junctions was sequenced using primers designed to produce short amplicons suitable for  
36  
37 degraded formalin-fixed DNA.(19) LOH studies were performed using a previously described  
38  
39 set of six polymorphic short tandem repeat markers (D1S517, D1S2785, D1S180, AFM214xe11,  
40  
41 D1S547 and D1S2842), surrounding the *FH* gene.(19) Additional patients with suspected  
42  
43 HLRCC were offered *FH* germline testing as part of their clinical care. This clinical genetic  
44  
45 testing was performed using massively parallel sequencing for small nucleotide variants with  
46  
47 Sanger confirmation and Multiplex Ligation-dependent Probe Amplification (MLPA) for  
48  
49 detection of large scale deletions.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Results**  
5

6 *Pathology evaluation of cases by FH and 2SC immunohistochemistry*  
7  
8

9 Over 3000 cases from multiple institutions were reviewed to select possible study cases that  
10 fulfilled the search criteria (spanning the years 1996-2014). We identified 124 tumors (from 118  
11 patients) for additional IHC evaluation by FH and 2SC using representative whole slide sections.  
12  
13 Most of the re-reviewed cases not included in the study remained “unclassified” after review, but  
14 additional IHC or other testing was not performed on excluded cases to further assess their  
15 classification. An IHC result indicating FH deficiency (FH -, 2SC 2+) was found in 24/124  
16 (19%) cases (Fig. 1A-C) and 73/124 (59%) showed retained FH function by IHC (FH +, 2SC 0)  
17 (Fig. 1D-F). Indeterminate IHC profile, when only one of the markers was suggestive of FH  
18 deficiency (FH + with 2SC 1+ to 2+; or FH +/- with 2SC 2+) was found in 27/124 (22%) cases  
19 (Fig. 2A-F). All FH negative cases (FH score 0) also demonstrated diffuse strong positive  
20 staining for 2SC (2SC 2+). In the FH-deficient cases, 2SC (2+) was diffusely and strongly  
21 positive in the cytoplasm in all cases; in only 35% of cases a distinct nuclear staining could be  
22 confirmed, while in the remaining cases the nuclear staining was difficult to evaluate due to  
23 strong cytoplasmic reactivity. In the cases considered indeterminate for FH expression, 2SC  
24 reactivity was restricted only to the cytoplasm.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 *TMA evaluation by FH and 2SC immunohistochemistry*  
49

50 Of the TMA evaluated cases, only 2/381 (0.5%) papillary RCC, both initially considered type 2  
51 (pt #2 and #17) (3% of all type 2 papillary RCC), showed FH deficient result (FH -, 2SC 2+)  
52 (Fig. 3A-C). All other tumor types evaluated on TMA, which included 232 clear cell RCC, 21  
53 chromophobe RCC, 25 oncocytomas, 39 other RCC, and 78 urothelial carcinomas demonstrated  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 retained FH expression, which was somewhat variable, but typically of moderate to strong  
5  
6 intensity, while the corresponding 2SC staining was considered negative in all evaluated cases  
7  
8 (FH+, 2SC 0).  
9

### 10 11 12 13 14 ***Molecular evaluation of FH mutations***

15  
16 The IHC results for FH and 2SC for FH-deficient cases and the corresponding *FH* mutational  
17  
18 alterations are shown in Table 1. We performed molecular testing on 64 cases, of which 57  
19  
20 produced informative result. We analyzed 21/26 cases considered FH-deficient by IHC (24  
21  
22 identified on whole slide and 2 on TMA by IHC). We also evaluated 26/27 cases considered FH  
23  
24 indeterminate by IHC and 10/73 cases which showed retained FH expression by IHC.  
25  
26  
27  
28  
29  
30

31 Mutations were found in 19/21 FH-deficient tumors, while in 2 cases mutations could not be  
32  
33 identified (one had low DNA quality and in neither case were large scale deletions sought by  
34  
35 MLPA). 9/19 cases underwent germline testing and the *FH* mutations were confirmed germline  
36  
37 in all tested cases, while the remaining 10/19 cases, which harboured *FH* inactivating mutations,  
38  
39 had only neoplastic FFPE tissue available for testing and germline mutations could not be  
40  
41 confirmed. Of 26 FH indeterminate tumors, only 1 case demonstrated *FH* mutation with IHC  
42  
43 profile: FH +/-, 2SC 2+ (Figure 2D-F), but no specific germline testing was performed. The  
44  
45 remaining 25/26 demonstrated wild type *FH* (IHC profile: 21 (FH +, 2SC 1+); 3 (FH +, 2SC 2+);  
46  
47 and 1 (FH -, 2SC 2+). All 10 cases with normal FH function (FH+, 2SC 0) by IHC showed wild  
48  
49 type *FH*.  
50  
51  
52  
53  
54  
55  
56  
57

### 58 ***Clinicopathologic findings in FH deficient RCC***

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 The clinico-pathologic findings in 27 FH-deficient RCC are shown in Table 2. They were almost  
5  
6 twice as common in men (M:F=1.9:1), with a median patient age of 44 years (mean 44; range 21  
7  
8 to 65 years). Twenty-one patients were Caucasians; one patient each was Asian and African-  
9  
10 American. Skin leiomyomas were documented in 3/23 (13%) patients and 5/8 (63%) female  
11  
12 patients had prior uterine leiomyomas; of note, FH was also negative by IHC in 2/2 females with  
13  
14 tested uterine leiomyomas. Family history of either renal tumors, skin or uterine leiomyomas was  
15  
16 elicited in 6/23 (26%) patients. Overall, an association with HLRCC syndrome was documented  
17  
18 in 8/23 (35%) patients, based on the presence of skin and uterine leiomyomas in the patients or  
19  
20 their kindreds, familial history of syndromic features, and *FH* mutational alterations. There was a  
21  
22 predilection for the left kidney (L:R=1.5:1). Solitary tumors were found in 21/23 (91%) patients  
23  
24 and 2 patients had bilateral tumors (one had multiple neoplasms in both kidneys). Average tumor  
25  
26 size was 8.2cm (median 8.5cm, range 0.9 to 18cm). 57% of patients had stage  $\geq$ pT3 and 52%  
27  
28 had positive nodes at surgery; in 19% patients distant metastatic disease (M1) was also found at  
29  
30 presentation. After a mean follow-up of 27 months (median 17.5, range 1-114 months), 39%  
31  
32 (9/23) patients were dead of disease and 26% (6/23) had disease progression, with evidence of  
33  
34 local recurrence or subsequent regional or distant metastases.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 The 27 FH-deficient neoplasms were characterized by variable and different architectural growth  
47  
48 patterns and typically two or more patterns were found in 93% of cases, as shown in Table 3.  
49

50  
51 Although papillary pattern was most commonly present and seen in 74% of cases (in 59% as a  
52  
53 dominant one), other common patterns were also seen: solid in 44%, (dominant in 22%),  
54  
55 tubulocystic in 41% (dominant in 7%), cribriform in 41% (dominant in 4%) and cystic in 33%  
56  
57 (not seen as dominant). Tubulopapillary was a dominant pattern in 1 case (4%); 1 (4%) case  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 showed sarcomatoid differentiation as a dominant morphology. Examples of different  
5  
6 morphologic growth patterns are illustrated in Figure 4A-F. By design, all cases demonstrated at  
7  
8 least focal macronucleoli, which in some cases were ubiquitous. In cases with papillary pattern,  
9  
10 typically there was absence of foam cells in the fibrovascular cores; hyalinization of the  
11  
12 fibrovascular cores was noted in 9 (45%) cases.  
13  
14  
15  
16  
17  
18

## 19 **Discussion**

20  
21 In this study we demonstrated that one fifth of RCC, diagnosed either as “unclassified RCC, high  
22  
23 grade” or “unclassified RCC with papillary pattern”, are FH-deficient by IHC and were almost  
24  
25 invariably accompanied by *FH* mutations. Only 0.5% of all cases diagnosed previously as  
26  
27 papillary RCC, and 3% of those considered type 2 papillary RCC, showed FH-deficiency by IHC  
28  
29 and *FH* mutations, while all other evaluated renal tumors showed retained FH expression. The  
30  
31 FH-deficient RCCs shared remarkable clinico-pathologic similarities with HLRCC-associated  
32  
33 RCC, including younger age at presentation, aggressive clinical behaviour and adverse  
34  
35 morphologic features, and were characterized predominantly by papillary architecture, typically  
36  
37 admixed with other growth patterns, with invariable presence of at least focal macronucleoli. In  
38  
39 fact, we were able to document an association with HLRCC syndrome in 8/23 (35%) of patients.  
40  
41 By IHC, these tumors typically demonstrated FH-deficient profile (FH -) with aberrant  
42  
43 succination, resulting in diffuse and strong 2SC reactivity (2+), which has previously been  
44  
45 shown to be strongly associated with HLRCC-related RCC.(13, 14) The IHC profile, along with  
46  
47 the morphology, aggressive clinical behaviour, and the presence of *FH* mutations, provide strong  
48  
49 justification to consider these tumors as part of the spectrum of the HLRCC-associated RCC.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 We believe that both antibodies, FH and 2SC, should be used simultaneously to enhance the IHC  
5  
6 potential in detecting FH-deficient RCC. Combined negative staining for FH and strong positive  
7  
8 staining for 2SC demonstrated very good sensitivity for FH-deficient RCC profile and excellent  
9  
10 specificity. That is, a normal pattern of staining for FH and 2SC can be used to rule out FH  
11  
12 deficiency in the great majority of renal carcinomas encountered. However, we identified 2  
13  
14 tumors (patient #19 and #21, 2<sup>nd</sup> tumor) with variably retained FH expression by IHC; both  
15  
16 tumors showed *FH* point mutations (2SC 2+ in both cases). As previously shown, possible  
17  
18 missense or other in-frame *FH* mutations may be associated with retained FH expression,  
19  
20 resulting from a synthesis of a stable, but inactive enzyme.(13-15, 20) In addition, all cases  
21  
22 considered “indeterminate” on IHC due to 2SC 1+ (21 cases) or 2SC 2+ (3 cases), but showing  
23  
24 retained FH expression (FH +), exhibited wild type *FH*. Therefore, restricting the evaluation to  
25  
26 only one of the antibodies would be limited by the relatively lower sensitivity of FH and the  
27  
28 lower specificity of 2SC. We also found it difficult to reliably confirm if 2SC reactivity was  
29  
30 nuclear, when diffuse and strong cytoplasmic reactivity was present. This is in contrast to Chen  
31  
32 Y-B et al(14) who found both cytoplasmic and nuclear 2SC to be present in HLRCC-associated  
33  
34 RCC, allowing them to distinguish it from the “cytoplasmic only” pattern observed in a  
35  
36 proportion of papillary RCC, type 2 and some unclassified, high grade RCC cases. The clinical  
37  
38 utility of the 2SC antibody is also currently limited, because it is not yet commercially available  
39  
40 and cannot be routinely used in surgical pathology laboratories. Given the lower specificity and  
41  
42 the difficulty in interpretation of 2SC, negative FH appears to be a more specific and comparably  
43  
44 sensitive test at the present time.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Recent studies have also shown that IHC reactivity for 2SC(21) or 2SC in combination with FH  
5  
6 (20, 22) aid in identifying FH-deficient leiomyomas in younger patients, associated with HLRCC  
7  
8 syndrome. We have previously shown that although the great majority of patients with HLRCC  
9  
10 syndrome will have FH deficient leiomyomas, 1% of all sporadic uterine leiomyomas are FH  
11  
12 deficient usually due to somatic inactivation.(22) This is in contrast to the current study, where  
13  
14 germline *FH* mutations were identified in all patients with FH-deficient RCC with sufficient  
15  
16 material for testing.  
17  
18  
19  
20  
21  
22

23  
24 The RCC associated with HLRCC syndrome have been reported in about 30% of HLRCC  
25  
26 families.(4, 12) HLRCC-associated RCC are particularly difficult to manage because they are  
27  
28 highly aggressive and present with advanced stage and metastatic disease, resulting in death of  
29  
30 disease in 40-50% patients.(9, 10) Therefore, active surveillance is not recommended for the  
31  
32 management of even small HLRCC-associated renal tumors in families with HLRCC syndrome,  
33  
34 and wide surgical excision is recommended when any renal tumor is detected.(10) RCC  
35  
36 associated with HLRCC syndrome are however quite rare and clinically challenging to diagnose  
37  
38 in practice, because patients frequently do not exhibit the whole spectrum of the clinical  
39  
40 presentations and the family association is either unknown or not apparent; clinical  
41  
42 manifestations can also differ within families (9, 10) The initial report described renal tumors in  
43  
44 32% of the patients, all with metastatic disease at presentation,(2) with a prevalence of 14%  
45  
46 reported by the National Cancer Institute (NCI) group in a North American cohort.(4) Kidney  
47  
48 cancers have lower penetrance than the skin or uterine leiomyomas in the HLRCC affected  
49  
50 families and they typically occur more than a decade later.(4, 9, 12) Therefore, patients may  
51  
52 initially present only with skin or uterine leiomyomas or less commonly with renal cell  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 carcinoma, and renal tumors may demonstrate a delayed presentation or the patients may lack the  
5 other HLRCC syndromic features. In the largest cohort of 38 patients with renal tumors, reported  
6  
7 by Merino et al from the NCI, 39% had documented skin leiomyomas and 55% had uterine  
8  
9 leiomyomas.(9) The morphology remains crucial in recognizing these tumors in routine practice.  
10  
11  
12  
13  
14

15  
16 In a recent study of comprehensive molecular characterization of papillary RCC, 3.1% (5/161) of  
17  
18 all papillary RCC and 8.3% (5/60) of those diagnosed as papillary type 2, demonstrated germ-  
19  
20 line or somatic *FH* mutations, which were associated with the CpG Methylator Phenotype  
21  
22 (CIMP).(23) Similar to our study, these patients were younger at presentation, and had a lower  
23  
24 probability of overall survival than other patients with papillary RCC. A subset of these papillary  
25  
26 RCC type 2 tumors, designated as CIMP-associated, shared the *FH*-deficient profile observed in  
27  
28 HLRCC-associated RCC, based on their molecular features, allowing for more accurate  
29  
30 characterization, which may lead to disease-specific targeted therapies.(23) This also highlights  
31  
32 the fact that the differential diagnosis of *FH*-deficient RCC will typically include papillary RCC  
33  
34 type 2, which is a relatively common renal tumor. However, the frequent papillary morphology  
35  
36 in combination with additional architectural patterns, and at least focal presence of  
37  
38 macronucleoli, should be regarded as morphologic clues to undertake additional IHC testing for  
39  
40 *FH* and 2SC in this setting.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 Currently, there is a lack of uniformly accepted definition of HLRCC-associated RCC, which is  
52  
53 defined not just by mutational analysis, but also clinically. The NIH definition requires that the  
54  
55 diagnosis of HLRCC is established with the identification of a heterozygous pathogenic variant  
56  
57 in *FH* in combination with multiple cutaneous leiomyomas, with at least one histologically  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 confirmed leiomyoma, a single leiomyoma in the presence of a positive family history of  
5  
6 HLRCC, and/or one or more tubulo-papillary, collecting-duct, or papillary type 2 renal tumors  
7  
8 with or without a family history of HLRCC. For the time being, “*FH-deficient RCC*” may be the  
9  
10 most appropriate nomenclature for tumors that show IHC negative staining for FH and strong  
11  
12 2SC reactivity, in the setting of uncertain clinical and family history and unknown genetic  
13  
14 status.(24) Taking a pragmatic approach, we would recommend that if FH-deficient RCC is  
15  
16 diagnosed, the possibility of HLRCC should be first considered clinically. If there is a suggestive  
17  
18 personal or family history, a presumptive diagnosis of HLRCC can be made pending  
19  
20 confirmation with formal genetic counselling and germline mutation testing. When FH-deficient  
21  
22 RCC is diagnosed in the absence of features suggesting syndromic disease, there is little data to  
23  
24 indicate the risk of germline mutation. Based on our limited data (the finding of germline *FH*  
25  
26 mutation in all 9 patients who had sufficient material available for testing), at this stage we  
27  
28 believe the risk of germline mutation (that is HLRCC) is very high, and therefore performing  
29  
30 genetic counselling and mutational analysis would be appropriate in all patients with FH-  
31  
32 deficient renal carcinoma. This recommendation may be modified in the future if, similar to FH-  
33  
34 deficient uterine leiomyoma, a low rate of germline mutation is found in follow-up studies.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 The tumorigenic effect of mutated *FH* results in fumarate accumulation, which acts as a  
46  
47 metabolic tumor suppressor, resulting in a metabolic shift toward aerobic glycolysis with  
48  
49 decreased oxidative phosphorylation (so-called Warburg effect). It has been postulated that this  
50  
51 alteration has possible downstream effects by inhibiting the hypoxia inducible factor prolyl  
52  
53 hydroxylase and increasing the hypoxia-inducible factor 1 alpha (HIF1alpha), which targets  
54  
55 vascular endothelial growth factor (VEGF), erythropoietin (EPO) and glucose transporter  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 1(GLUT1), and produces additional epigenetic alterations of genome-wide histone and DNA  
5  
6 methylation, leading to increased cell proliferation and tumorigenesis.(3, 24-26) On a molecular  
7  
8 level, these changes have also been characterized by increased oxidative stress and activation of  
9  
10 the NRF2-antioxidant response elements (ARE) pathway.(23, 27, 28)  
11  
12  
13  
14

15  
16 Limitations of this study include its retrospective nature, which allowed us to confirm association  
17  
18 with HLRCC syndrome only in about a third of patients with FH-deficient RCC. For example, in  
19  
20 some cases we were not able to obtain a dermatological confirmation of skin leiomyomatosis,  
21  
22 and a complete family history on specific HLRCC features was not available. Although  
23  
24 mutational analysis was performed on FFPE neoplastic tissue in the majority of tested cases, a  
25  
26 formal *FH* genetic testing was done only in a subset of cases, perhaps with a selection bias  
27  
28 towards patients with a high likelihood of familial disease, limiting the ability to confirm  
29  
30 germline *FH* mutations. In 2 FH-deficient cases by IHC, we could not confirm the presence of  
31  
32 *FH* mutations; one of the 2 cases demonstrated low DNA quality and additional studies to  
33  
34 investigate for possible *FH* mutations in these 2 cases, for example, by MLPA to screen for large  
35  
36 scale *FH* deletions were not performed.  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 In summary, we found that a substantial number of cases considered either as “unclassified RCC,  
47  
48 high grade” or “unclassified RCC with papillary pattern”, and small percent of cases diagnosed  
49  
50 as papillary RCC type 2, demonstrated FH-deficient pattern (FH -, 2SC 2+) by IHC and were  
51  
52 invariably accompanied by *FH* mutations at the molecular level. Although we could document  
53  
54 an unequivocal association with HLRCC syndrome in only about a third of the patients, there is  
55  
56 clearly a high likelihood of syndromic disease in patients presenting with FH-deficient RCC.  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Furthermore, even apparently sporadic FH-deficient RCC show striking clinico-pathological similarities to unequivocally HLRCC syndrome-associated renal carcinomas, including a younger age and adverse features at presentation, aggressive clinical behaviour, and frequent papillary architecture in combination with other growths patterns, with invariable presence of at least focal macronucleoli. In addition to the careful morphologic evaluation, IHC for FH and 2SC is a useful aid that allows recognition of the RCC with FH-deficient profile with FH IHC being more specific and 2SC being more sensitive.

1  
2  
3  
4 Figure legends:  
5

6  
7 Figure 1

8  
9 An FH-deficient RCC showing a papillary growth pattern (A). The cells exhibit eosinophilic  
10 macronucleoli with perinucleolar clearing (inset) (patient #6). On IHC, neoplastic cells  
11 demonstrate FH negative staining, while non-neoplastic cells show granular cytoplasmic  
12 staining, used as positive internal control (B). 2SC shows diffuse and strong staining in the  
13 neoplastic cells (2+) (C). In cases with retained FH expression, such as in this example with  
14 papillary growth pattern (D), FH shows diffuse staining in the neoplastic cells (E), while 2SC is  
15 negative (F).  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 Figure 2

27  
28 Some cases demonstrated indeterminate IHC profile for FH, with only one of the markers  
29 suggestive of FH deficiency while the other was equivocal or negative. In this example showing  
30 papillary growth (A), FH demonstrated retained expression (B), while 2SC showed variable  
31 staining pattern (1+) (C); no *FH* mutation was identified on molecular analysis. In another  
32 example with indeterminate IHC profile (D), FH showed focal expression (E), but 2SC was  
33 diffusely positive (2+) (F). On molecular analysis, *FH* mutation was identified in this case  
34 (patient #19).  
35  
36  
37  
38  
39  
40  
41  
42  
43

44  
45 Figure 3

46  
47 We identified 2 cases on TMA with FH-deficient pattern, originally considered papillary RCC  
48 type 2 (A). Both cases showed prominent eosinophilic nucleoli (inset). In both cases, FH was  
49 negative (B), while 2SC was strongly positive (C). *FH* mutation was confirmed in the illustrated  
50 tumor from the patient #2.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Figure 4  
5  
6

7 FH-deficient RCC were characterized by various architectural growth patterns with two or more  
8 patterns present in great majority of cases. Papillary pattern was most commonly present as a  
9 dominant one (A) and hyalinization of the papillary fibrovascular cores was frequent (B). In this  
10 example, an admixed tubulocystic pattern is also seen (right) (B). Other frequent patterns  
11 included solid, in this example with foci resembling collecting-duct carcinoma (C), cribriform  
12 (D), cystic, which in this example also shows intracystic papillary growth (E) and tubular, which  
13 in this example shows multiple intracytoplasmic vacuoles imparting admixed cribriform  
14 morphology (F).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

1. Kiuru M, Lehtonen R, Arola J, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. *Cancer Res*. 2002 Aug 15;62(16):4554-7.
2. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. *Proc Natl Acad Sci U S A*. 2001 Mar 13;98(6):3387-92.
3. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nature genetics*. 2002 Apr;30(4):406-10.
4. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. *Am J Hum Genet*. 2003 Jul;73(1):95-106.
5. Kiuru M, Launonen V, Hietala M, et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. *Am J Pathol*. 2001 Sep;159(3):825-9.
6. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. *Hum Mol Genet*. 2003 Jun 1;12(11):1241-52.
7. Kloepfer HW, Krafchuk J, Derbes V, Burks J. Hereditary multiple leiomyoma of the skin. *Am J Hum Genet*. 1958 Mar;10(1):48-52.
8. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. *Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*. World Health Organization; Geneva: World Health Organization; 2004.
9. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. *Am J Surg Pathol*. 2007 Oct;31(10):1578-85.
10. Grubb RL, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. *J Urol*. 2007 Jun;177(6):2074-9; discussion 2079-80.
11. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. *Am J Surg Pathol*. 2013 Oct;37(10):1469-89.
12. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet*. 2006 Jan;43(1):18-27.
13. Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. *Biochim Biophys Acta*. 2011 Nov;1807(11):1432-43.
14. Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. *Am J Surg Pathol*. 2014 May;38(5):627-37.
15. Chen YB, Kong MX, Bialik A, et al. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cancer: a comparison of fumarate hydratase (FH) and S-(2-succino)-cysteine (2SC) immunohistochemistry as ancillary tools. *Mod Pathol*. 2015;28(Suppl 2):211A.
16. Lara-Otero K, Linehan MW, Merino MJ. IHC Helps to identified renal tumors associated with HLRCC Syndrome. *Mod Pathol*. 2014;(Suppl 2):243A.
17. Toon CW, Hasovits C, Paik J, et al. Skin rash, a kidney mass and a family mystery dating back to World War II. *Med J Aust*. 2014 Jul 7;201(1):58-60.
18. Udager AM, Alva A, Chen YB, et al. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma. *Am J Surg Pathol*. 2014 Apr;38(4):567-77.

19. Martinek P, Grossmann P, Hes O, et al. Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). *Virchows Arch*. 2015 Aug;467(2):185-91.
20. Joseph NM, Solomon DA, Frizzell N, et al. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients. *Am J Surg Pathol*. 2015 Nov;39(11):1529-39.
21. Reyes C, Karamurzin Y, Frizzell N, et al. Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. *Mod Pathol*. 2014 Jul;27(7):1020-7.
22. Harrison WJ, Andrici J, Maclean F, et al. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. *Am J Surg Pathol*. 2015 Nov 16.
23. Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 4:1-11.
24. Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. *Clin Cancer Res*. 2013 Jul 1;19(13):3345-52.
25. Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. *Genes Dev*. 2012 Jun 15;26(12):1326-38.
26. Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. *BMC Med Genet*. 2008;9:20.
27. Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. *Cancer Cell*. 2011 Oct 18;20(4):511-23.
28. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. *Mol Cell Biol*. 2009 Aug;29(15):4080-90.

**TABLE 1.** FH and 2SC immunohistochemistry and *FH* molecular alterations in fumarate hydratase-deficient RCC

Patient	FH IHC	2SC IHC	<i>FH</i> mutation status
1	-	++	c.1189G>A, p.Gly397Arg
2	-	++	c.174_177dupTGAAA, p.Leu60Ter
3	-	++	c.496G>T, p.Gly166Ter
4	-	++	Large scale deletion of whole of <i>FH</i> on MLPA (Germline)
5	-	++	c.413_414del, p.Leu138fs (Germline)
6	-	++	Large scale deletion of <i>FH</i> and <i>OPN3</i> gene on MLPA (Germline)
7	-	++	c.689A>G, p.Lys230Arg (Germline)
8	-	++	NA (pt deceased before consent)
9	-	++	c.239dupA, p.Ile81AspfsTer14
10	-	++	Negative
11	-	++	c.911_917 del CTTTTGT(Phe 305Leufs*22)
12	-	++	NA
13	-	++	c.1385_1390+6del
14	-	++	NA
	-	++	Negative (low quality DNA)
15	-	++	LOH positive ( <i>FH</i> wt, sample with abundant non-tumor tissue)
16	-	++	c.395_398delTAAAT, p.Leu132Ter
17	-	++	c.805delA, p.Ile269fsTer15
18	-	++	NA
19	-/+	++	c.139C>T, p.Gln47Ter
20	-	++	c.320A>C, p.Asn107Thr (Germline)
21	-	++	c.698G>A, p.Arg233His (Germline)
	+	++	c.698G>A, p.Arg233His
22	-	++	c.1189G>A, p.Gly397Arg (Germline)
	-	++	c.1189G>A, p.Gly397Arg (Germline)
	-	++	c.1189G>A, p.Gly397Arg (Germline)
23	-	++	NA (pending, recent case)



**TABLE 2.** Clinical characteristics of patients with fumarate hydratase-deficient RCC

Pt	Sex	Age	Leiomyomas	Family History	Side	Greatest size (cm)	pTNM stage	Metastasis	Follow-up (mo)	Status
1	M	65	No	Unk	L	18	T3aN1	Liver, lung, spleen and bone at presentation	3	DOD
2	M	62	Unk	Unk	L	10	T2aN0		114	AND
3	M	60	No	Unk	R	8	T2aNX		7	AND
4	F	25	Uterine at 25 (FH-)	Yes*	R	4	T1aNX		17	AND
5	M	44	Unk	Yes†	R	4.5	T3aN0		7	AND
6	M	25	Skin	Yes‡	R	14	T3aN1	Liver, flank wall at 6 months	64	DOD
7	F	32	Uterine	Yes§	L	3	T1aNX	Left para-aortic lymph nodes	56	AWD
8	M	35	Unk	Unk	R	10	T3aN1	Para-aortic lymph node	18	DOD
9	M	51	Unk	Unk	R	14	NA		96	AND
10	M	46	Unk	Unk	L	10	T3aN1	Bone (multiple)	24	DOD
11	M	44	Unk	Unk	NA	8	NA	Lung, lymph nodes at 6 months	6	AWD
12	F	40	Unk	Unk	L	9	T3aN1	Peritoneum, retroperitoneum, lymph nodes, omentum	24	DOD
13	M	52	Unk	Unk	R	14	T4N1	Lung, mediastinum	13	DOD
14	M	41	No	Unk	L**	1	T1aNX	Similar hilar tumor resected after 1 year (see below)	13	AWD
		42	No	Unk	L	4	T3aN1	Perihilar lymph node	13	
15	F	21	No	Yes¶	L	5.5	T3aNX		12	AND
16	M	42	Unk	No	L	10	T2N0	Aorta involvement	18	DOD
17	M	21	No	Unk	L	5	T4N1M1	Bone (rib), retroperitoneal nodes	4	AWD
18	M	46	Unk	Unk	NA	NA	T3bN1M1	NA	12	DOD
19	F	50	Unk	Unk	L	10.9	T2N0		18	AND
20	F	59	Skin, uterine	Unk	L	12.5	T4N1M1	Liver, lung, supraclavicular and iliac lymph nodes (direct into adrenal, pancreas)	1	DOD
21	F	51	Skin, uterine at 31	Yes#	L	1.4††	T1aNX		46	AWD
		51			R	0.9	T1aNX		46	
22	M	56	No	Unk	R	3.5‡‡	T3aN0		31	AWD
	M	56	No	Unk	L	9	T2aNX			
	M	57	No	Unk	R	4	T1aNX	Probable local recurrence (same side tumor)		
23	F	43	Uterine at 38 (FH -)	Unk	L	12.5	T3aN1M1	Bone (tibia)	1	AWD

Abbreviations: DOD=died of disease, AWD=alive with disease, AND=alive no disease, NA=not available, Unk=unknown

\*Uncle had kidney removed in 2009 for multiple tumours; †Twin brother died from metastatic 'kidney cancer'; ‡Mother with multiple uterine leiomyomas, grandfather died of renal carcinoma and had multiple skin lesions (not further characterised); §Mother and one sister tested positively for *FH* gene; ¶Father and paternal grandmother with "skin lesions"; #Maternal aunt with "renal tumors"; \*\*Two similar RCC resected from left kidney (second after 12 mo); ††Bilateral multiple renal tumors; ‡‡Bilateral renal tumors, second tumor on in the right kidney possibly local recurrence

**TABLE 3.** Morphologic patterns seen in fumarate hydratase-deficient RCC. Dominant patterns are marked by asterisk.

Case	Papillary	Solid	Tubulocystic	Cribriform	Cystic	Tubular	Sarcomatoid	Tubulopapillary	# of Patterns
1		+	+				+		3
2	+	+			+	+		+	5
3	+		+	+	+				4
4		+	+		+				3
5	+	+				+		+	4
6	+								1
7	+	+			+				3
8	+				+			+	3
9	+				+				2
10	+		+						2
11				+		+			2
12	+			+	+	+			4
13		+				+	+		3
14	+	+	+						3
15	+	+	+		+				4
16	+					+			2
17	+		+	+					3
18	+	+							2
19								+	1
20	+					+			2
21		+					+		2
22	+		+	+					3
23	+		+	+					3
24	+	+		+					3
25	+		+		+				3
26		+		+			+		3
27	+		+	+					3
Total	20/27 (74%)	12/27 (44%)	11/27 (41%)	11/27 (41%)	9/27 (33%)	7/27 (26%)	4/27 (15%)	4/27 (15%)	







